Relmada Therapeutics (RLMD) Competitors $1.81 +0.15 (+9.04%) Closing price 09/26/2025 04:00 PM EasternExtended Trading$1.80 -0.02 (-0.83%) As of 09/26/2025 07:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RLMD vs. SOPH, VOR, TRDA, TLSA, TNYA, SLS, MDWD, EPRX, CCCC, and DERMShould you be buying Relmada Therapeutics stock or one of its competitors? The main competitors of Relmada Therapeutics include SOPHiA GENETICS (SOPH), Vor Biopharma (VOR), Entrada Therapeutics (TRDA), Tiziana Life Sciences (TLSA), Tenaya Therapeutics (TNYA), SELLAS Life Sciences Group (SLS), MediWound (MDWD), Eupraxia Pharmaceuticals (EPRX), C4 Therapeutics (CCCC), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry. Relmada Therapeutics vs. Its Competitors SOPHiA GENETICS Vor Biopharma Entrada Therapeutics Tiziana Life Sciences Tenaya Therapeutics SELLAS Life Sciences Group MediWound Eupraxia Pharmaceuticals C4 Therapeutics Journey Medical SOPHiA GENETICS (NASDAQ:SOPH) and Relmada Therapeutics (NASDAQ:RLMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, dividends, media sentiment, institutional ownership, valuation and profitability. Does the media favor SOPH or RLMD? In the previous week, SOPHiA GENETICS had 2 more articles in the media than Relmada Therapeutics. MarketBeat recorded 6 mentions for SOPHiA GENETICS and 4 mentions for Relmada Therapeutics. Relmada Therapeutics' average media sentiment score of 1.11 beat SOPHiA GENETICS's score of 0.45 indicating that Relmada Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SOPHiA GENETICS 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Relmada Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in SOPH or RLMD? 31.6% of SOPHiA GENETICS shares are held by institutional investors. Comparatively, 45.2% of Relmada Therapeutics shares are held by institutional investors. 4.9% of SOPHiA GENETICS shares are held by company insiders. Comparatively, 20.7% of Relmada Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts rate SOPH or RLMD? SOPHiA GENETICS presently has a consensus target price of $8.00, indicating a potential upside of 93.70%. Relmada Therapeutics has a consensus target price of $1.00, indicating a potential downside of 44.75%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than Relmada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings and valuation, SOPH or RLMD? SOPHiA GENETICS has higher revenue and earnings than Relmada Therapeutics. SOPHiA GENETICS is trading at a lower price-to-earnings ratio than Relmada Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$65.17M4.28-$62.49M-$0.44-9.39Relmada TherapeuticsN/AN/A-$79.98M-$2.22-0.82 Is SOPH or RLMD more profitable? Relmada Therapeutics has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -40.99%. SOPHiA GENETICS's return on equity of -30.69% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-40.99% -30.69% -17.39% Relmada Therapeutics N/A -223.17%-180.41% Which has more risk and volatility, SOPH or RLMD? SOPHiA GENETICS has a beta of 1.01, suggesting that its stock price is 1% more volatile than the S&P 500. Comparatively, Relmada Therapeutics has a beta of 0.74, suggesting that its stock price is 26% less volatile than the S&P 500. SummarySOPHiA GENETICS beats Relmada Therapeutics on 10 of the 15 factors compared between the two stocks. Get Relmada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RLMD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RLMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RLMD vs. The Competition Export to ExcelMetricRelmada TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$55.10M$2.51B$5.63B$10.32BDividend YieldN/A58.03%5.79%4.65%P/E Ratio-0.8223.8175.7526.14Price / SalesN/A518.39526.41121.04Price / CashN/A172.2337.1160.83Price / Book1.535.1712.416.36Net Income-$79.98M$32.95M$3.29B$270.97M7 Day Performance18.30%2.40%1.27%0.34%1 Month Performance170.35%5.97%3.43%6.06%1 Year Performance-46.29%-8.14%63.29%27.34% Relmada Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RLMDRelmada Therapeutics2.8902 of 5 stars$1.81+9.0%$1.00-44.8%-44.8%$55.10MN/A-0.8210Positive NewsSOPHSOPHiA GENETICS1.9293 of 5 stars$3.17+1.6%$8.00+152.4%+7.8%$210.85M$65.17M-7.20520VORVor Biopharma2.6681 of 5 stars$1.60-8.0%$6.07+279.2%+128.7%$202.69MN/A-0.97140Analyst UpgradeGap DownTRDAEntrada Therapeutics2.7444 of 5 stars$5.06-4.2%$25.67+407.2%-63.2%$200.84M$210.78M-2.84110News CoverageTLSATiziana Life Sciences0.5847 of 5 stars$1.70+0.6%N/A+98.1%$197.47MN/A0.008News CoverageGap UpHigh Trading VolumeTNYATenaya Therapeutics2.8435 of 5 stars$1.20flat$6.25+420.8%-17.8%$195.57MN/A-1.25110SLSSELLAS Life Sciences Group1.3916 of 5 stars$1.68-9.2%$7.00+316.7%+28.3%$194.80M$1M-5.2510MDWDMediWound1.3819 of 5 stars$17.14-3.9%$32.25+88.2%+7.0%$192.81M$20.22M-6.4980News CoveragePositive NewsEPRXEupraxia Pharmaceuticals2.0889 of 5 stars$5.30-0.4%$11.00+107.5%+118.3%$191.13MN/A-6.2429Gap UpCCCCC4 Therapeutics3.4869 of 5 stars$3.57+34.2%$8.67+142.8%-64.2%$189.31M$35.58M-2.26150Analyst ForecastHigh Trading VolumeDERMJourney Medical2.3886 of 5 stars$7.12+0.1%$12.17+70.9%+29.1%$187.06M$56.40M-18.7490Positive News Related Companies and Tools Related Companies SOPHiA GENETICS Alternatives Vor Biopharma Alternatives Entrada Therapeutics Alternatives Tiziana Life Sciences Alternatives Tenaya Therapeutics Alternatives SELLAS Life Sciences Group Alternatives MediWound Alternatives Eupraxia Pharmaceuticals Alternatives C4 Therapeutics Alternatives Journey Medical Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RLMD) was last updated on 9/27/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Relmada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Relmada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RLMD Stock Alerts